ROCKVILLE, MD and SHENZHEN, CHINA, June4, 2024—HighTide Therapeutics, Inc. (Stock Code: 2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced to

ROCKVILLE, MD and SHENZHEN, CHINA, May 14, 2024—HighTide Therapeutics, Inc. , a globally integrated biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for metabolic and digestive diseases, announced toda

The FII PRIORITY Asia Summit is taking place in Hong Kong. Dr. Liping Liu, Founder and CEO of HighTide Therapeutics, Inc. (HighTide) was invited to present at the summit on the topic of How to Upgrade the Human-tech Interface?.

ROCKVILLE, MD and SHENZHEN, CHINA, November 2, 2023—HighTide Therapeutics, Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for metabolic and digestive diseases

HighTide Therapeutics, Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for metabolic and digestive diseases, today announces that the company’s founder and CEO,

ROCKVILLE, MD and SHENZHEN, CHINA, October 20, 2023— HighTide Therapeutics, Inc. (HighTide), a biopharmaceutical company developing novel multifunctional multi-targeted therapies for metabolic